News Alzamend Neuro, Inc.

Equities

ALZN

US02262M4078

Market Closed - Nasdaq Other stock markets 21:30:00 01/05/2024 BST			5-day change	1st Jan Change
0.718 ^USD	+0.98%		+1.24%	-19.33%

03-25	Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	CI
01-31	Alzamend Neuro, Inc. announced that it expects to receive $6 million in funding from Ault Lending, LLC	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	03-25	CI
Alzamend Neuro, Inc. announced that it expects to receive $6 million in funding from Ault Lending, LLC	01-30	CI
Alzamend Neuro, Inc. Appoints Milton C. Ault, III as a Director and Vice Chairman	01-05	CI
Alzamend Neuro, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	12-15	CI
Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients	12-12	AQ
Alzamend Neuro, Inc. Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients	12-11	CI
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients	12-11	BU
Alzamend Neuro Receives FDA Approval to Proceed With Phase 2A Study of AL001 Depression Treatment Candidate	11-20	MT
Alzamend Neuro Gets FDA Approval for Trial of Depression Treatment	11-20	DJ
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients	11-20	BU
Alzamend Neuro Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients	11-20	CI
Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement	11-17	AQ
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement	11-16	BU
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001	11-13	BU
Alzamend Neuro, Inc. Submits IND Application for A Phase IIa Clinical Trial in Post-Traumatic Stress Disorder Patients of Next-Generation Lithium Therapeutic Drug Candidate AL001	11-13	CI
Wall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed Meeting	30/10/23	MT
Alzamend Neuro Announces Reverse Stock Split	30/10/23	BU
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next-Generation Lithium Therapeutic Drug Candidate AL001	24/10/23	AQ
Alzamend Neuro Seeks FDA Nod to Start Trial in Major Depressive Disorder	23/10/23	MT
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001	23/10/23	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Alzamend Neuro, Inc.

Equities

ALZN

US02262M4078

Summary

Filters